A combined oro-nasopharyngeal swab is more sensitive than mouthwash in detecting SARS-CoV-2 by a high-throughput PCR assay

Wiebke Michel1 · Jacqueline Färber1 · Milica Dilas1 · Hans-Gert Heuft2 · Ina Tammer1 · Jannik Baar1 · Achim J. Kaasch1

Received: 17 October 2020 / Accepted: 1 March 2021 / Published online: 18 March 2021
© The Author(s) 2021

Abstract
Objectives The optimal diagnostic specimen to detect SARS-CoV-2 by PCR in the upper respiratory tract is unclear. Mouthwash fluid has been reported as an alternative to nasopharyngeal and oropharyngeal swabs. We compared mouthwash fluid with a combined oro-nasopharyngeal swab regarding test performance.

Methods In a large refugee facility, we retested individuals with a previous positive test for SARS-CoV-2 and their quarantined close contacts. All individuals were asymptomatic at the time of testing. First, a mouthwash (gargling for at least 5 s) with sterile water was performed. Then, with a single flocked swab the back of the throat and subsequently the nasopharynx were sampled. Samples were inactivated and analysed on a Roche cobas 6800® system with the Roche SARS-CoV-2 test.

Results Of 76 individuals, 39 (51%) tested positive for SARS-CoV-2 by oro-nasopharyngeal swab. Mouthwash detected 13 of 76 (17%) infections, but did not detect any additional infection. Samples that were positive in both tests, had lower cycle threshold (Ct)-values for oro-nasopharyngeal samples, indicating a higher virus concentration, compared to samples only positive in oro-nasopharyngeal swabs.

Conclusion Mouthwash is not as sensitive as combined oro-nasopharyngeal swab in detecting upper respiratory tract infection.

Keywords Diagnostic accuracy · Sensitivity · Specificity · COVID19 · SARS2 · Mouthwash · Oronasopharyngeal swab

Introduction
In December 2019, a new lung disease called Coronavirus Disease 2019 (COVID-19) first appeared in Wuhan, China, and subsequently spread globally [1]. The causative agent is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA virus. Together with SARS-1 and MERS coronavirus it is classified in the Orthocoronaviridae subfamily, genus Betacoronavirus [2].

SARS-CoV-2 is efficiently transmitted from person to person by respiratory droplets [3]. Rapid and accurate detection of the virus is essential to contain outbreaks. One recommended diagnostic specimen for SARS-CoV-2 detection is the nasopharyngeal swab [4], but combined naso-oropharyngeal swabs can increase the sensitivity of SARS-CoV-2 detection [5]. A meta-analysis of different SARS-CoV-2 studies showed the highest detection rates in sputum, followed by nasopharyngeal and then oropharyngeal swab samples [6]. In severe cases of COVID-19 or at later stages in the disease, SARS-CoV-2 can be detected in samples from the lower respiratory tract, such as sputum or bronchial aspirate [7].

Expected shortages of swabs and the unpleasant experience of a nose swab as reported during an outbreak in a refugee facility led us to assess alternative diagnostic specimens. Although, available evidence at that time suggested that saliva was a suitable specimen [8], we decided against using saliva for two reasons: first, our main automated PCR
system is sensitive to viscous samples such as saliva; and second, saliva may not be produced in sufficient quantity by all subjects. Therefore, we decided to test mouthwash as a specimen. To rigorously assess test performance, we compared mouthwash and a combined oro-nasopharyngeal swab in a study population with expected low viral loads.

**Methods**

The study was conducted in a large refugee facility on two occasions in May 2020 during an outbreak in the facility. Residents (age > 6 years) of the facility that were previously tested positive for SARS-CoV-2 (n = 63) and their quarantined close contacts (family members, roommates and friends, n = 13) were prospectively enrolled in the study. Participants were retested for SARS-CoV-2 with mouthwash and a combined oro-nasopharyngeal swab in controlled conditions. Each individual entered the study only once with the first positive sample. Samples were taken by previously instructed medical personnel. A single flocked swab (eSwab™ Copan) was used to sample the back of the throat and subsequently the deep nasopharynx. For the mouthwash, residents were instructed to gargle the mouth with 10 ml sterile water for at least 5 s under the supervision of medical personnel. All residents were interviewed for any symptoms in the preceding three weeks that were compatible with a SARS-CoV-2 infection using a questionnaire with the following items: fever, tiredness, dry cough, sneezing, body ache, nasal congestion, sore throat, diarrhoea, headache, shortness of breath, loss of smell or taste, or any other symptoms. Interviews and sample collection took place with the assistance of interpreters; gargling was demonstrated, if necessary.

Samples were transported at room temperature and stored overnight at 4 °C. All samples were mixed 1:1 with ATL buffer and analysed with the cobas® SARS-CoV-2 assay on the Roche cobas 6800 system according to the manufacturer’s instructions. Detection of the E-(envelope)-gene and Orf1/a (open reading frame 1) or only E-gene or only Orf1/a were interpreted as confirmation of SARS-CoV-2 infection. Cycle threshold (Ct)-values above 40 were considered as negative.

**Results**

Overall, 76 individuals were tested. Of these, 63 individuals had a previous positive PCR-test for SARS-CoV-2 at a median time of 14 days prior and 13 individuals were in quarantine as close contacts. Among the quarantined close contacts, five new infections were detected in a second round of testing, whereas seven did not contract the infection. Age ranged from 7 to 59 years, with an average age of 29 years (Table 1). At the time of testing, no individual showed any symptoms of COVID-19. 26 individuals collected symptoms compatible with COVID-19 in the past three weeks (Table 1): headache (12 individuals), cough (10), rhinitis (9), loss of taste (6), fatigue (5), mild shortness of breath (4), aching limbs (4), sore throat (3), fever (3), diarrhoea (2), and sneezing (2). In some of the individuals, the symptoms lasted only one day. None was hospitalised.

In 39 of the 76 participants (51%), PCR of the combined oro-nasopharyngeal swab confirmed SARS-CoV-2 infection. In contrast, SARS-CoV-2 was detected in 13 mouthwashes (17%) of which all were positive by the oro-nasopharyngeal swab (Table 2). When considering the oro-nasopharyngeal swab as gold standard, the sensitivity of mouthwash was 33%.

The cycle threshold (Ct)-value is a measure for the abundance of the transcript in the sample and correlates with viral load. When comparing Ct-values of oro-nasopharyngeal swabs, specimens that were positive by mouthwash had lower Ct-values than specimens negative by mouthwash, indicating a lower viral load in mouthwash (Fig. 1a). Samples that were positive by both methods showed higher Ct-values in the mouthwash (Fig. 1b). All results are consistent with a lower sensitivity of detection in mouthwash.

**Discussion**

The shortage of swabs that are suitable for PCR diagnostics is a serious issue in public health, and the unpleasant experience frequently reported with oro-nasopharyngeal swabs, in particular in children, led us to explore the utility of mouthwash in a controlled study. We found a very low sensitivity of mouthwash (33%), when using oro-nasopharyngeal swabs as comparator. We speculate that this striking difference in sensitivity is partly due to the dilution of the mouthwash sample. Thus, mouthwash is not suitable for the reliable detection of SARS-CoV-2 infection.

Only one other small study compared throat washings and swabs [9]. In this study, the rate of detection of SARS-CoV-2 was higher in self-collected throat washings with sterile normal saline than in nasopharyngeal swabs [9]. However, the small sample size of 11 patients does not allow firm conclusions.

Our study has several strengths: we conducted the study in a controlled setting with specifically trained personnel. This allows for a more rigorously sampling than in an observational study conducted in the clinical setting. As gold standard, we chose combined oro-nasopharyngeal swabs. A systematic review that assessed the positivity rate of different specimens found that nasopharyngeal swabs had a slightly higher positivity rate than oro-pharyngeal swabs,
A combined oro-nasopharyngeal swab is more sensitive than mouthwash in detecting SARS-CoV-2...

with larger differences when sampling was performed more than 14 days after symptom onset [6].

Our study population were asymptomatic individuals, with a previous positive PCR-test for SARS-CoV-2 and their close contacts. Since the viral load decreases over time, this population is expected to have a low viral load and thus high Ct-values. Indeed, 34 of 39 (87%) positive samples had Ct-values above 30 for the E-gene, a value currently discussed as a cut-off for infection. Thus, this study was designed to rigorously assess differences in sensitivity.

Our study has also limitations. Although mouthwash with gargling was conducted under supervision, we observed some variation in adherence to the protocol regarding the duration and intensity of gargling, which may have influenced the results. Furthermore, we did not compare different RNA extraction methods, which may show a better performance with mouthwash specimens.

There is a high likelihood of aerosol formation during gargling. Thus, mouthwash should be performed alone in a well-ventilated area. This may limit its use in patients to minimise exposure of health-care personnel. In conclusion, SARS-CoV-2 detection with mouthwash showed a low sensitivity compared to oro-nasopharyngeal swabs. Thus, we do recommend performing combined oro-nasopharyngeal swabs, especially in patients with no or mild symptoms.

Table 1  Overview of the study population stratified by age

| Category                                      | Number of individuals by age group (in years) |
|-----------------------------------------------|-----------------------------------------------|
|                                               | N=1  | N=11 | N=37 | N=14 | N=7  | N=6  | N=76 |
| Male/female                                   | 0/1  | 9/11 | 30/7 | 12/7 | 5/2  | 5/1  | 61/15|
| Positive PCR-test preceding study and positive test at time of study | 0     | 8     | 17   | 5    | 2    | 2    | 34   |
| Positive PCR-test preceding study, but negative test at time of study | 0     | 1     | 16   | 7    | 2    | 3    | 29   |
| Negative PCR-test preceding study, but positive test at time of study | 0     | 2     | 1    | 1    | 1    | 0    | 5    |
| Negative PCR-test preceding study and negative test at time of study | 1     | 0     | 3    | 1    | 2    | 1    | 8    |
| Individuals with symptoms male/female         | 0/0  | 5/0  | 12/3 | 3/1  | 1/0  | 1/0  | 22/4 |
| Symptoms (male/female)                        |      |      |      |      |      |      |      |
| Aching limbs                                  | 3/0  | 1/0  | 4/0  |      |      |      |      |
| Cough                                         | 7/2  | 1/0  | 8/2  |      |      |      |      |
| Diarrhoea                                     | 1/0  | 1/0  | 2/0  |      |      |      |      |
| Fatigue                                       | 3/1  | 1/0  | 4/1  |      |      |      |      |
| Fever                                         | 3/0  | 1/0  | 3/0  |      |      |      |      |
| Headache                                      | 1/0  | 6/2  | 2/0  | 1/0  | 10/2 | 6/0  |      |
| Loss of smell or taste                        | 5/0  | 1/0  | 6/0  |      |      |      |      |
| Rhinitis                                      | 2/0  | 5/1  | 8/1  |      |      |      |      |
| Mild shortness of breath                      | 3/1  | 3/1  | 3/1  |      |      |      |      |
| Sneezing                                      | 1/0  | 1/0  | 2/0  |      |      |      |      |
| Sore throat                                   | 1/0  | 1/1  | 2/1  |      |      |      |      |
| Missing reports                               | 1/0  | 3/0  | 5/0  |      |      |      |      |

All individuals were asymptomatic at the time of study and had a history of exposure to SARS-CoV-2. Reported symptoms occurred within the previous three weeks.

Table 2  Comparison of mouthwash and combined oro-nasopharyngeal swab in detecting SARS-CoV-2

| Category               | Oro-nasopharyngeal swab positive | Oro-nasopharyngeal swab negative | Total |
|------------------------|----------------------------------|----------------------------------|-------|
| Mouthwash positive     | 13                               | 0                               | 13    |
| Mouthwash negative     | 26                               | 37                              | 63    |
| Total                  | 39                               | 37                              | 76    |

The sensitivity of mouthwash is 33%, the specificity 100% when using the combined oro-nasopharyngeal swab as gold standard (McNemar test p value < 0.001)
Acknowledgements
We thank the technical personnel of the Institute of Medical Microbiology and Hospital Hygiene and the Institute of Transfusion Medicine, Medical Faculty, Otto-von-Guericke University Magdeburg, for technical support.

Author contributions
AJK and IT designed the study; MD, JB, IT, HGH, and AJK conducted the investigation; WM, JB, and AJK edited, reviewed and interpreted the data; WM and AJK wrote the original draft and all authors approved the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Declarations
Conflict of interest
JF reports personal fees from Biomérieux and the Medical Association of Saxony-Anhalt, outside the submitted work; WM, MD, HGH, IT, JB and AJK report no conflicts of interest. There was no specific funding for this study.

Ethical statement
The study was performed according to the principles of the Declaration of Helsinki. Approval was obtained from the ethics committee of the Medical Faculty of the Otto-von-Guericke University Magdeburg (approval number 74/20). Written informed consent was obtained from all participants or their guardians.

Fig. 1 The combined oro-nasopharyngeal swab has a higher sensitivity than mouthwash. a Cycle threshold (Ct) values for Orf1/α- and E-gene for oro-nasopharyngeal swabs in samples positive and negative in mouthwash. A lower Ct-value indicates a higher viral load. Ct-values (mean, standard deviation [range]): for E-gene positive samples 31.46, 4.96 [19.9–36.8]; for E-gene negative samples 35.67, 2.71 [26.4–38.4]; Orf1/α-gene positive samples 30.37, 4.23 [19.9–34.4]; Orf1/α-gene negative samples 33.17, 2.90 [25.8–38.5], respectively. Mann-Whitney U-test E-gene: p value < 0.001, Orf1/α-gene: p value = 0.036. b Ct-values for samples positive in both specimen types. Ct-values for the mouthwash (mean, standard deviation [range]: E-gene 34.85, 1.53 [32.4–37.3]; Orf1/α-gene 32.9, 1.2 [31.4–35.6]) were higher than for the combined oro-nasopharyngeal swabs (E-gene 31.46, 4.96 [19.9–36.8]; Orf1/α-gene 30.21, 4.37 [19.9–34.4]), indicating a lower viral load in mouthwash. Only 12 paired samples were shown, since one sample was positive in the E-gene and another in the Orf1/α-gene, only (Wilcoxon signed rank test E-gene: p value = 0.007, Orf1/α-gene: p value = 0.037).

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017.
2. Ludwig S, Zarbock A. Coronavirus and SARS-CoV-2: A brief overview. Anesth Analg. 2020;131:93–6. https://doi.org/10.1213/ANE.0000000000004845.
3. WHO. Scientific Brief: Transmission of SARS-CoV-2: implications for infection prevention precautions. 2020. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions.
A combined oro-nasopharyngeal swab is more sensitive than mouthwash in detecting SARS-CoV-2…

4. Department of Communications, WHO Global. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. WHO Reference Number: WHO/COVID-19/laboratory/2020.5. 2020. https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.

5. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol. 2020;30:e2106. https://doi.org/10.1002/rmv.2106.

6. Mohammadi A, Esmaeizadeh E, Li Y, Bosch RJ, Li J. SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis. EBioMedicine. 2020;102903. ISSN 2352-3964. https://doi.org/10.1016/j.ebiom.2020.102903.

7. Wang K, Zhang X, Sun J, et al. Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019. Chest. 2020;158:1876–84. https://doi.org/10.1016/j.chest.2020.06.015.

8. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a noninvasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020;58:e00776-e820. https://doi.org/10.1128/JCM.00776-20.

9. Guo WL, Jiang Q, Ye F, et al. Effect of throat washings on detection of 2019 novel coronavirus. Clin Infect Dis. 2020;71:1980–1. https://doi.org/10.1093/cid/ciaa416.